Lantheus (NASDAQ:LNTH) Rating Lowered to “Hold” at StockNews.com

StockNews.com lowered shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a report released on Thursday.

LNTH has been the subject of a number of other reports. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Trading Up 1.0 %

Shares of NASDAQ LNTH opened at $87.32 on Thursday. Lantheus has a one year low of $50.20 and a one year high of $126.89. The business has a fifty day simple moving average of $103.76 and a 200 day simple moving average of $96.59. The firm has a market capitalization of $6.07 billion, a price-to-earnings ratio of 14.53 and a beta of 0.51.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of LNTH. Russell Investments Group Ltd. increased its stake in shares of Lantheus by 10.4% in the first quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock valued at $2,347,000 after buying an additional 3,560 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Lantheus by 8.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 21,088 shares of the medical equipment provider’s stock valued at $1,313,000 after acquiring an additional 1,670 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its position in shares of Lantheus by 30.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider’s stock worth $3,116,000 after purchasing an additional 11,696 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Lantheus during the first quarter valued at approximately $1,432,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.